Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost,
morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

BACKGROUND Until recently, biomarker testing in heart failure (HF) syndromes has been
viewed as an elective supplement to diagnostic evaluation of patients suspected to suffer …

Heart failure (HF) biomarkers have dramatically impacted the way HF patients are evaluated
and managed. B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are the …

New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Heart failure is a clinical condition with complex pathophysiology that involves many
different processes. Diagnosis is often difficult in patients presenting for the first time with …

Since natriuretic peptides were successfully integrated into the clinical practice of heart
failure (HF), the possibility of using new biomarkers to advance the management of affected …

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. Circulating
biomarkers reflecting pathophysiological pathways involved in HF development and …

Plasma biomarkers are useful tools in the diagnosis and prognosis of heart failure (HF). In
the last decade, numerous studies have aimed to identify novel HF biomarkers that would …